Introduction
Sirtuinsa re NAD +-dependenth istoned eacetylase enzymes (HDACs) that function as regulators of many cellularp rocesses.
[1] To date, seven sirtuins (SIRT1-7)h ave been identified [1a] that are evolutionarilyconserved, existing in av ariety of organisms from eukaryotet oh umans. The catalytic activityo fs irtuins has been closely associated with deacetylation of histones, however,t hey have also been shown to deacetylate non-histone proteins, [2] demonstrating their role in pathways controlling aging, cancers, and metabolic diseases. [1a] AlthoughS IRT6 has been less studied than SIRT1-3, it has gained interestina ge-associated diseases because of its role in variousc ellular functions, such as genomic stability,o xidative stress, and glucosem etabolism. [3] SIRT6-deficient mice presented with apremature aging phenotype accompanied by ashortened lifespan, [1b, 4] whereas overexpression of SIRT6 prolonged the lifespan of male mice and prevented physiological damage caused by diet-induced obesity. [5] SIRT6 was shown to play a role in several cancers ubtypes as well, as either at umor suppressoro rp romoter,o rb oth.
[6] Consequently SIRT6 has been identified as ap otentialt herapeutic target in the context of age-associated diseases, cancer, and metabolic disorders, including obesity and insulin-resistant diabetes. [5, 7] In addition to its deacetylationa ctivity,S IRT6 possesses mono-ADP-ribosyltransferase activity [8] and carrieso ut deacylation of long-chain fatty acyl groups from lysines. [9] In fact, the catalytic activityo fS IRT6 was demonstrated to preferentially hydrolyzel ong-chain fatty acyl groups over deacetylation in vitro [9] by af actor of 300. Furthermore,i tw as found that whereas deacetylation was specifict oH3K9 and H3K56, hydrolysis of the corresponding myristoyl peptidew as observed for the aforementioned peptidesa sw ell as fort he H2K12 sequence. [9] Subsequently,D enu and collaborators found that fatty acids-oleic,m yristic, palmitic, stearic, linoleic, and a-linolenic acids-increased SIRT6 deacetylationa ctivity, [10] with myristic acid increasing deacetylase activity by the greatest magnitude (tenfold), with an EC 50 value of 246 mm.O leic and linoleic acids were found to be the most effective at increasing SIRT6 activity,a lbeit by only five-to sixfold, with EC 50 values of 100 mm. SIRT6 hasa lso been shown to be involved in rosiglitazonemediated metabolic regulation. [11] When rosiglitazone, ap eroxisome proliferator-activated receptor (PPAR)-g agonist, wasa dministered to rats, it increased the expression of SIRT6, PPAR-g coactivator1 -alpha (PGC-1a), and fork-head box O1 (Foxo1) protein, as well as causing increases in both liver kinaseB1 (LKB1)a nd 5'-adenosine monophosphate-activated protein kinase (AMPK) activities.W hen SIRT6 wasa bsent, the effects of rosiglitazone on hepatocytef at accumulationc eased, suggesting that rosiglitazone protects against hepatic steatosis by activating the SIRT6-AMPK pathway.T he data suggestedi nteractions between the nuclear receptor PPAR-g and SIRT6. Similarly, Jin et al. demonstrated that fisetin,af lavanol, increased deacetylationo fP GC-1a by SIRT1 and, as ar esult, increased its interaction with the PPAR complex and increased transcription. [12] Several other flavonoids, including quercetin and luteolin, were also identified as SIRT6 inhibitors.
[13]
The biological activity of endogenous fattya cid ethanolamides, N-acylethanolamines (NAEs), has recently been demonstratedt ob em ediated by PPAR-a [16-18a] and PPAR-g, [17] as well as by other targets. For example, anandamide bound to and induced PPAR-g gene expression, [14] whereas oleoylethanolSirtuin 6( SIRT6) is an NAD +-dependenth istoned eacetylase enzyme that is involved in multiple molecular pathways related to aging. Initially,i tw as reportedt hat SIRT6 selectively deacetylated H3K9Aca nd H3K56Ac;h owever,i th as more recently been shown to preferentially hydrolyze long-chainf atty acyl groups over acetyl groups in vitro. Subsequently,f atty acids were demonstrated to increase the catalytic activity of SIRT6. In this study,w ei nvestigated whether as eries of N-acylethanolamines (NAEs), quercetin, and luteolin could regulate SIRT6 activity.N AEs increased SIRT6 activity,w ith oleoylethanolamide having the strongest activity (EC 50 value of 3.1 mm). Quercetin and luteolin were demonstrated to have dual functionality with respectt oS IRT6 activity;n amely,t hey inhibited SIRT6 activity with IC 50 values of 24 and 2 mm,r espectively,a nd stimulated SIRT6 activity more than sixfold (EC 50 valueso f9 90 and 270 mm,respectively).
amide bound to and increased the transcriptional activity of PPAR-a. [15] NAEs are ag roup of endogenous compounds involved in av ariety of physiological processes, including energy homeostasis and inflammation. [16] As ar esult of their physiological actions, and due to previous studies demonstrating that fatty acidsc an activate SIRT6, [9] [10] as eries of NAEs (Table 1) were tested for activity against the SIRT6 protein by using an in vitro H3K9 deacetylation assay. Quercetin and luteolin,p reviously identified SIRT6 inhibitors, were also tested for SIRT6 activity.
Results and Discussion
AS IRT6 in vitro assay was developed to determine the functional activity of SIRT6 regulators. The reaction conditions for the developed assay were optimized depending on whether inhibition or activation assays were being conducted. H3K9Ac, an H3-based substrate for SIRT6 that is frequently used to measureS IRT6 activity,w as used in this study.T he ratio of the deacetylated histone (H3K9) to H3K9Acw as used to measure the activity of the enzyme. Various concentrations of H3K9Ac (10-300 mm)a nd SIRT6 enzyme( 1-10 mg), (Figure S1 Ai nt he Supporting Information) as well as different incubation times, were studied (Figure S1 B). All tested concentrations of SIRT6 were within al inear range, with the exceptiono f1mgmL À1 , which resultedi nn od etectable deacetylated histone. The deacetylation activity of SIRT6 (3 mgmL À1 )w as subsequently demonstrated to be linear from 15 min to 2h.The initial rate velocities at varying concentrations of substrate H3K9Ac were measured, andt he data were fitted to the Michaelis-Menten equation to yield K m and V max values of 232 mm and 87 pmol mg The SIRT6 deacetylation assay was carried out with 40 mm H3K9Aca nd a3 0min incubation time when testing for activators. The assay was validated by determining the deacetylation activity in the presence of 100 mm of as et of known SIRT6 activators, including oleic acid, linoleic acid, and stearic acid (Figure 2A) . [10] Oleic and linoleica cid weres trong activators of SIRT6, whereas stearic acid displayed very little activity,c onsistent with the literature. [10] As ar esult, functional activity was determined for both oleic and linoleica cid, which stimulated SIRT6 in ad ose-dependent manner, with EC 50 values of 89 AE 15 mm and 230 AE 10 mm,r espectively ( Figure 2B ), similart op reviously reported values of 90 and 100 mm. [10] The SIRT6 inhibition assayw as optimized, and it was determined that 150 mm H3K9Acand a60min incubation time were optimal. We previously demonstrated that as eries of flavonoids had significant inhibitory effects on the deacetylation activity of SIRT6; [13] as ar esult, quercetin and luteolin were used as positive controls. Both quercetin and luteolin inhibited SIRT6 deacetylase activity in ac oncentration-dependent manner (Table 1) , with an IC 50 value of 24 and 4.1 mm,r espectively,c onsistent with previousr eported values. [13a, 17] Further- www.chembiochem.org more, they both inhibitedSIRT6 deacetylation activity to asimilar extent (38a nd 30 %, respectively). As eries of ethanolamides (Scheme 1)-arachidonoyl (AEA), linoleoyl( LEA), a-linolenoyl (A-LEA), g-linolenoyl( G-LEA), myristoyl (MEA), oleoyl( OEA), palmitoleoyl (POEA), palmitoyl( PEA), and stearoyl (STEA)-were tested for SIRT6 activity at 100 mm, as this concentration was effective at activating SIRT6 for fatty acids. All NAEs increased SIRT6 activity,w ith the exception of STEA and AEA, with a~1.5-fold increase for g-LEA to a~2.1-fold increasef or OEA (data not shown). Therefore, the concentrationw as decreased to 10 mm to determinew hich NAEs were most active towardS IRT6 ( Figure 3A) . As can be seen, OEA, MEA and PEA increased SIRT6 activity by the greatest extent with at wofold increase, similar to what was observed with 100 mm linoleica cid (Figure 2A) . Interestingly,l inoleic acid was able to stimulate SIRT6 more efficiently than the corresponding ethanolamide, LEA. Although NAEs stimulated SIRT6 deacetylase activity at concentrationsof10mm,the magnitude of stimulation was greater with fatty acids. Similar results were obtained by using the His-tagged SIRT6 protein ( Figure S2 ), thus confirming that the activation was not the result of any interaction with the GST fusion protein. As OEA andM EA stimulated SIRT6 activity by the greatest extent forb oth the GST and His-tagged SIRT6, ad ose-response curve forM EA and OEA (0.02-100 mm)w as determined. SIRT6 activity increased for both MEA andO EA in ad ose-dependent manner,w ith EC 50 valueso f7 .5 AE 3a nd 3.1 AE 2 mm,r espectively ( Figure 3B ), with at wofold increase in activity (Table 1 ). The EC 50 values obtained were below the circulating physiological concentrations [18] of OEA and MEA;h owever,t he resulting intranuclear concentrationo fO EA was sufficientf or activation of PPAR-a, for whichO EA has been reported to have an EC 50 in the 100 nm to mm range and therefore could be expected to be sufficient to activateS IRT6. [19] The dose-response curve used to determinet he IC 50 values of quercetin and luteolin resulted in an increasei na ctivity at higher concentrations (> 300 mm). As aresult, the deacetylation activation assay was carriedo ut for quercetin and luteolin at ac oncentration range from 50 mm to 10 mm.Q uercetin increasedt he activity of SIRT6 tenfold, with an EC 50 value of 990 mm,w hereas luteolin increased SIRT6 activity~sixfold, with an EC 50 of 270 mm (Table 1, Figure 4 ). [20] The binding of the myristoylated peptidet ot he SIRT6 co-crystal structure was determined and revealed al arge hydrophobic pocket that responsible for binding the long-chain fatty acyl groups [9] to the protein.T he bindingo ff atty acids to this pocket was shown to induce ac onformational change that stimulated deacetylation activity [10] and might also be the site where the NAEs bind. In the case of quercetin and luteolin, they might bind to SIRT6 at low concentrations,p reventing NAD+ + from binding and thereby decreasing SIRT6 activity, whereas at higher concentrations,t hey might induce as imilar conformational change induced by fatty acids that resultsi n increased activity.
Scheme1.Structures of N-acylethanolamines (NAEs).

Conclusion
The identification of NAEs as SIRT6 activators, specifically,O EA and MEA with EC 50 values of 3a nd 4 mm,r espectively,c ould identify an ovel mechanism of action for the NAEs.I nterestingly,a lthough quercetin and luteolin both elicited dose-dependent inhibition of SIRT6 deacetylation activity as previously reported, [17] they also displayed as ignificant increase( six-to tenfold) of SIRT6 deacetylation activity at higherd oses.T he identificationo fN AEs and the flavonoids as activators of SIRT6 expands the multiple roles of SIRT6.
Experimental Section
Chemicals: Acetylated histone H3 (K9) peptide (residues 1-21; H3K9Ac) was purchased from AnaSpec Incorporation (Fremont, MI, USA). Luteolin, nicotinamide adenine dinucleotide (NAD), formic acid, and long-chain fatty acid derivatives (linoleic, oleic, and stearic acids) were ordered from Sigma-Aldrich. Ethanolamide derivatives (arachidonoyl, linoleoyl, a-linolenoyl, g-linolenoyl, myristoyl, oleoyl, palmitoleoyl, palmitoyl, and stearoyl) were purchased from Cayman Chemical Company (Ann Arbor,M I, USA). His-tagged human recombinant SIRT6 was ordered from Biovision Inc. (Milpitas, CA, USA).
Expression and purification of GST-tagged SIRT6 protein: The human SIRT6 expression vector hSIRT6-pGEX-6P3 was kindly provided by Prof. Katrin Chua (Stanford, CA, USA). The recombinant GST-tagged SIRT6 was produced by fermentation in Escherichia coli BL21(DE3)-pRARE. Production occurred at + +16 8Cw ith 0.1 mm IPTG for 20 h, and the soluble overexpressed protein was affinityp urified on glutathione agarose (Sigma-Aldrich).
Optimization of the SIRT6 deacetylation assay: To ensure optimal experimental conditions, the reaction linearity with varying SIRT6 enzyme amounts, reaction times, or H3K9Ac substrates was determined for the assay.T he reaction mixture contained H3K9Ac (75-150 mm), NAD (500 mm ), and recombinant SIRT6 (1-10 mg/well) in Tris buffer (25 mm,pH8.0). The reactions were initiated by addition of the recombinant SIRT6 to wells, incubated from 15 min to 4hat 37 8C, and quenched by adding formic acid (6 mL, final concentration:1%). The mixtures were centrifuged at 16 100 g for 15 min.
The linearity of reaction velocity was measured by varying H3K9Ac substrate (10-300 mm)a tv arious times points. Time points were selected so that steady-state initial velocities were maintained in all reactions. In the experiment, H3K9Ac was incubated with SIRT6 (3 mgp er well) and saturating NAD (3 mm)i nT ris buffer (25 mm, pH 8.0) at 37 8C, and the reaction was subsequently quenched by adding formic acid (6 mL, final concentration:1 0%). The data were fitted to the Michaelis-Menten equation by using GraphPad Prism software version 6. All experiments were carried out with aD MSO concentration of 1%.T he blank controls were carried out without recombinant SIRT6 enzyme or NAD.
HPLC analysis: The chromatographic separation of H3K9 and acetylated H3K9 was achieved on aZ orbax Eclipse XDB-C18 column (4.6 50mm, 1.8 mm; Agilent Te chnologies) at room temperature by using aS himadzu prominence system (Shimadzu, Columbia, MD) consisting of aC BM-20A, LC-20 AB binary pumps, an SIL-20AC-HT autosampler,a nd aD GU-20A3 degassing unit. The mobile phase consisted of water with 0.02 %f ormic acid (elute A) and acetonitrile with 0.02 %f ormic acid (elute B). The gradient eluent at af low rate of 0.9 mL min À1 was programmed as follows:0 -2.0 min, 0% B; 2.0-10 min, 0-8 %B;1 0-10.10 min, 8-80 %B;1 0.10-12 min, 80 %; 12-12.1 min 80-0 %B;1 5min, 0% B. The total run time was 15 min, and the injection volume per sample was 20 mL. The HPLC system was coupled to a5 500 QTRAP from Applied Biosystems/ MDS Sciex equipped with aT urbo Ve lectrospray ionization source (TIS;A pplied Biosystems). The data were acquired and analyzed by using Analyst version 1.5.1 (Applied Biosystems). Positive electrospray ionization data were acquired by multiple reaction monitoring (MRM). The TIS instrumental source settings for temperature, curtain gas, ion source gas 1( nebulizer), ion source gas 2( turbo ion spray), entrance potential, and ion spray voltage were 550 8C, 20 psi, 60 psi, 50 psi, 10 V, and 5500 V, respectively.T he TIS compound parameter settings for declustering potential, collision energy,a nd collision cell exit potential were 231, 45, and 12 V, respectively,f or H3K9Ac, and 36, 43, and 12 V, respectively for H3K9. The standards were characterized from the following MRM ion transitions:H 3K9Ac (m/z 766.339!760.690) and H3K9 (m/z 752.198!746.717).
SIRT6 deacetylation assay: Ligands were incubated for 30 min in the presence of SIRT6 (3 mg/well), H3K9Ac (40 mm), and NAD (500 mm)i nT ris buffer (25 mm,p H8.0) at 37 8C. During the reaction, the final solvent concentration of all samples was 1% DMSO. Fatty acids (linoleic, oleic, and stearic;1 00 mm)a nd ethanolamides, (AEA, LEA, A-LEA, G-LEA, MEA, OEA, POEA, PEA, and STEA;1 0mm) were tested against SIRT6.
EC 50 values were determined for linoleic acid, oleic acid, MEA, OEA, quercetin and luteolin. The concentrations ranged from 0.07 to 100 mm for MEA, from 0.02 to 100 mm OEA, from 70 to 2000 mm for linoleic acid and oleic acid, from 100 mm to 10 mm for quercetin, and from 50 mm to 5mm for luteolin. The EC 50 values were calculated by using GraphPad Prism Software version 6.
SIRT6 inhibition assay:
Under the defined assay conditions, inhibition of SIRT6 was determined in the presence of quercetin and luteolin. For this assay,S IRT6 (3 mg/well), H3K9Ac (150 mm), and NAD (500 mm)i nT ris buffer (25 mm,p H8.0) were incubated for 60 min at 37 8C. Concentrations varied from 2t o2 50 mm for quercetin and from 0.3 to 25 mm for luteolin. IC 50 values were calculated by using GraphPad Prism Software version 6. 
